Spine metastasis in the L5 vertebrae

Public health crisis

Approximately 2 million people are living with cancer in the UK and this number is set to rise considerably over the next decade to 3.2M. A significant complication of late stage (stage 4) cancer is metastases or secondary tumours which are caused by tumour cells spreading to different locations in the body.

Metastases are particularly associated with breast cancer, which is the most common cancer in females and the leading cause of cancer deaths in this group. According to Cancer Research UK, 150 people every day are diagnosed with breast cancer. Although more than 76% of people with the disease survive for more than ten years, some patients do develop stage 4 cancers, of which it is estimated about 50% to 60% get bone tumours.  

The tumours weaken the bone and lead to a variety of problems for the patients at a time when quality of life is a paramount consideration, especially as the prognosis is usually terminal.

Significant issues include severe pain and spinal fracture which may lead to spinal cord injury. These complications often require major surgery which encroaches, significantly, on the patients’ quality of life, when life expectancy is a matter of months and may, in certain cases, provide a mechanism of further spread of the cancer. Currently, there are no implants for supporting the bones before fracture as we cannot identify which vertebrae are likely to fail.

A more patient-friendly approach is realised in OncoEng in which we predict which vertebrae with tumours are likely to fail in the future enabling informed decision on care.

The Technology

Advanced computational modelling and imaging will be used to look at the growth of the tumour so that predictions of the strength of the vertebrae can be calculated at different points in time.

These strengths can then be compared to spinal loads and enable an assessment of fracture risk undertaken.

Those vertebrae at high risk would then receive special implant to support the weakened bone and prevent fracture.

This implant would only require key-hole surgery and would not impinge on the patient’s quality of life through a lengthy recuperation period or additional pain.

Learn more about the OncoEng research programme

The OncoEng Research Vision

A research collaboration between the University of Leeds, Imperial College London and UCL has received funding to develop an alternative approach based on developing new imaging and modelling techniques that will enable clinicians to predict which patients are at a high-risk of a vertebra fracturing.  

The project – Oncological Engineering: A new concept in the treatment of bone metastases – has attracted £7 million in research funding, including £5.6 million grant from the Engineering and Physical Sciences Research Council (EPSRC), part of UK Research and Innovation, the Government-funded body set up to support research and innovation. 

Within five years, the research team hope to have developed new techniques and materials that will revolutionise the treatment of bone metastases.  

The NHS Long Term Plan and the EU’s Beating Cancer Plan for cancer treatment had called on researchers to develop new interventions that would improve the quality of life of patients living with advanced cancers. 

It is hoped the new techniques will be applied to other areas of the healthcare sector.  

“The problem facing doctors is they have no way of knowing which of the spinal vertebrae is going to collapse. But when that happens, patients may require major surgery which involves a lengthy period of rehabilitation. 

Our approach is to intervene by developing new techniques and equipment that will prevent spinal fractures, crucially helping to maintain a patient’s quality of life at a time when they may be terminally ill. ”

Expert in medical engineering at the University of Leeds who is leading the new OncoEng research collaboration

Latest News

Exploring Metastatic Bone Disease Through Patient Narratives

As a mechanical engineer looking to develop methodologies to characterise spinal biomechanics and its perturbation due to metastatic bone disease (MBD), attending the OncoEng Patient Day was an eye-opening experience. This event provided an invaluable…

Birmingham Med-Tech Innovation Expo 2023

Blog written by Yash Karade and Aamena Lakdawala We bid farewell to Leeds on the morning of 7th June 2023 as we started our journey to the MedTech Expo in Birmingham. It was surely a…

World Cancer Day

The Leeds Cancer Research Centre will be delivering a mini-conference as part of World Cancer Day on the 3 rd February (World Cancer Day is actually on 4th Feb). OncoEng is very supportive of the…

OncoEng Quarterly Meeting

Great OncoEng Quarterly get together last week. The Management Board Meeting in the morning was eagerly attended by all the researchers and academics. In the afternoon we were joined by Dr Sherron Furtado, Craig Gerrand, Sarah Astill and David Lunn to…